Literature DB >> 12015835

Long-term results after stereotactic radiosurgery for patients with cavernous malformations.

Toshinori Hasegawa1, James McInerney, Douglas Kondziolka, John Y K Lee, John C Flickinger, L Dade Lunsford.   

Abstract

OBJECTIVE: Stereotactic radiosurgery has been used for patients with high-risk cavernous malformations of the brain. We performed radiosurgery for patients with symptomatic, imaging-confirmed hemorrhages for which resection was believed to be associated with high risk. This study examines the long-term hemorrhage rate after radiosurgery.
METHODS: We reviewed data obtained before and after gamma knife radiosurgery on 82 patients treated between 1987 and 2000. Most patients had multiple hemorrhages from brainstem or diencephalic cavernous malformations. Follow-up data were examined to identify hemorrhages, and an overall hemorrhage rate was calculated.
RESULTS: Observation before treatment averaged 4.33 years (range, 0.17-18 yr) for a total of 354 patient-years. During this period, 202 hemorrhages were observed, for an annual hemorrhage rate of 33.9%, excluding the first hemorrhage. Temporal clustering of hemorrhages was not significant. After radiosurgery, patient follow-up averaged 5 years (range, 0.42-12.08 yr), for a total of 401 patient-years. During this period, 19 hemorrhages were identified, 17 in the first 2 years posttreatment and 2 after 2 years. The annual hemorrhage rate was 12.3% per year for the first 2 years after radiosurgery, followed by 0.76% per year from Years 2 to 12. Eleven patients had new neurological symptoms without hemorrhage after radiosurgery (13.4%). The symptoms were minor in six of these patients and temporary in five.
CONCLUSION: Radiosurgery confers a reduction in the risk of hemorrhage for high-risk cavernous malformations. Risk reduction, although in evidence during initial follow-up, is most pronounced after 2 years. Given the difficulty of identifying high-risk patients, treatment after one major hemorrhage should be considered in selected younger patients. Such a strategy warrants further investigation.

Entities:  

Mesh:

Year:  2002        PMID: 12015835     DOI: 10.1097/00006123-200206000-00003

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

1.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

2.  Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Authors:  Aubrey C Chan; Stavros G Drakos; Oscar E Ruiz; Alexandra C H Smith; Christopher C Gibson; Jing Ling; Samuel F Passi; Amber N Stratman; Anastasia Sacharidou; M Patricia Revelo; Allie H Grossmann; Nikolaos A Diakos; George E Davis; Mark M Metzstein; Kevin J Whitehead; Dean Y Li
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

Review 3.  Cavernous malformations: natural history, diagnosis and treatment.

Authors:  Sachin Batra; Doris Lin; Pablo F Recinos; Jun Zhang; Daniele Rigamonti
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 4.  Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies.

Authors:  Shervin Taslimi; Amirhossein Modabbernia; Sepideh Amin-Hanjani; Fred G Barker; R Loch Macdonald
Journal:  Neurology       Date:  2016-04-22       Impact factor: 9.910

5.  Management of brainstem cavernous malformations.

Authors:  Tarek Y El Ahmadieh; Salah G Aoun; Bernard R Bendok; H Hunt Batjer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-06

6.  Development of de novo cavernous hemangioma after radiosurgery for cavernous hemangioma.

Authors:  Je Young Yeon; Yeon-Lim Suh; Jong-Hyun Kim; Jung-Il Lee
Journal:  J Korean Neurosurg Soc       Date:  2010-12-31

7.  Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.

Authors:  David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

8.  Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.

Authors:  Rustam Al-Shahi Salman; Julie M Hall; Margaret A Horne; Fiona Moultrie; Colin B Josephson; Jo J Bhattacharya; Carl E Counsell; Gordon D Murray; Vakis Papanastassiou; Vaughn Ritchie; Richard C Roberts; Robin J Sellar; Charles P Warlow
Journal:  Lancet Neurol       Date:  2012-01-31       Impact factor: 44.182

Review 9.  Management of cerebral cavernous malformations: from diagnosis to treatment.

Authors:  Nikolaos Mouchtouris; Nohra Chalouhi; Ameet Chitale; Robert M Starke; Stavropoula I Tjoumakaris; Robert H Rosenwasser; Pascal M Jabbour
Journal:  ScientificWorldJournal       Date:  2015-01-05

10.  The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases.

Authors:  Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.